Aprea Therapeutics (APRE) Accumulated Expenses (2018 - 2026)

Aprea Therapeutics (APRE) has reported Accumulated Expenses for 9 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 505.67% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 505.67% YoY), while the FY2025 annual figure was $2.1 million, up 340.99% from the prior year.
• Accumulated Expenses grew to $2.4 million in Q1 2026 per APRE's latest filing, from $2.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $4.5 million in Q1 2022 and bottomed at $285207.0 in Q1 2024.
• Historically, Accumulated Expenses has averaged $2.0 million across 5 years, with a median of $2.0 million in 2025.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 710.7% — and 2024, when it tumbled 91.61%.
• Aprea Therapeutics' Accumulated Expenses stood at $2.4 million in 2022, then plunged by 56.88% to $1.0 million in 2023, then slumped by 54.27% to $465015.0 in 2024, then jumped by 340.99% to $2.1 million in 2025, then increased by 14.88% to $2.4 million in 2026.
• Business Quant data shows APRE's Accumulated Expenses at $2.4 million in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.